← Back to Screener
Immutep Limited American Depositary Shares (IMMP)
Price$0.62
Favorite Metrics
Price vs S&P 500 (26W)-85.24%
Price vs S&P 500 (4W)24.51%
Market Capitalization$72.90M
All Metrics
Book Value / Share (Quarterly)$0.05
P/TBV (Annual)2.57x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-49.93%
Cash Flow / Share (Quarterly)$0.00
Price vs S&P 500 (YTD)-86.50%
Net Profit Margin (TTM)-2030.67%
EPS (TTM)$-0.04
10-Day Avg Trading Volume78.06M
EPS Excl Extra (TTM)$-0.04
Revenue Growth (5Y)-66.35%
EPS (Annual)$-0.03
ROI (Annual)-42.29%
Net Profit Margin (5Y Avg)-31067.06%
Cash / Share (Quarterly)$0.05
Revenue Growth QoQ (YoY)17606.36%
ROA (Last FY)-39.13%
Revenue Growth TTM (YoY)7574.00%
EBITD / Share (TTM)$-0.04
ROE (5Y Avg)-33.92%
Operating Margin (TTM)-2153.84%
Cash Flow / Share (Annual)$-0.02
P/B Ratio1.03x
P/B Ratio (Quarterly)6.41x
EV / Revenue (TTM)7.30x
Net Interest Coverage (TTM)-2.30x
ROA (TTM)-55.17%
EPS Incl Extra (Annual)$-0.03
Current Ratio (Annual)11.69x
Quick Ratio (Quarterly)2.91x
3-Month Avg Trading Volume23.53M
52-Week Price Return-9.36%
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)1691.96x
Asset Turnover (Annual)0.00x
52-Week High$0.47
Operating Margin (5Y Avg)-34985.03%
EPS Excl Extra (Annual)$-0.03
CapEx CAGR (5Y)86.31%
Tangible BV CAGR (5Y)49.61%
26-Week Price Return-76.49%
Quick Ratio (Annual)11.02x
13-Week Price Return-84.60%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)2.97x
Enterprise Value$21.614
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)7.93%
Pretax Margin (Annual)-102219.92%
Cash / Share (Annual)$0.06
3-Month Return Std Dev262.19%
ROE (Last FY)-42.77%
Net Interest Coverage (Annual)-101.51x
EPS Basic Excl Extra (Annual)$-0.03
Receivables Turnover (TTM)0.26x
EV / Free Cash Flow (TTM)735.87x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.04
Receivables Turnover (Annual)0.10x
ROI (TTM)-68.40%
P/S Ratio (TTM)24.61x
Pretax Margin (5Y Avg)-31067.05%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.07
Price vs S&P 500 (52W)-6.15%
Year-to-Date Return-83.86%
5-Day Price Return71.79%
EPS Normalized (Annual)$-0.03
ROA (5Y Avg)-31.07%
Net Profit Margin (Annual)-102219.92%
Month-to-Date Return42.55%
Cash Flow / Share (TTM)$-0.03
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-116703.91%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-33.31%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.04
P/TBV (Quarterly)6.81x
P/B Ratio (Annual)2.44x
Pretax Margin (TTM)-2030.67%
Book Value / Share (Annual)$0.07
Price vs S&P 500 (13W)-87.46%
Beta3.52x
Revenue / Share (TTM)$0.00
ROE (TTM)-69.20%
52-Week Low$0.03
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMMPImmutep Limited American Depositary Shares | 24.61x | 7574.00% | — | — | $0.62 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Immutep is a Phase 3 clinical-stage biotechnology company developing LAG-3 immunotherapies to treat cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa (efti), is in a registrational Phase 3 trial for first-line non-small cell lung cancer. The company's diversified pipeline includes additional LAG-3-based programs targeting various solid tumors and autoimmune indications.